---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-041428"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:23:34.279756+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ChromaDex extends $10M revolving credit line maturity to Nov 2025; interest rate floor raised to 8.25%

## Summary
- Revolving credit line of up to $10M extended to November 12, 2025; no amounts outstanding as of filing.
- Interest rate changed to greater of 8.25% or Prime plus 1%; additional 5% during default event.
- Amendment requires maintaining at least 75% of consolidated cash at Western Alliance Bank starting Jan 31, 2024.
- $50,000 renewal fee paid; share repurchases limited to $2.5M aggregate during the term.
- Quick ratio covenant of 1.15:1.00 added to qualify for streamlined reporting period.

## SEC filing metadata
- accession: 0001628280-23-041428
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/cdxc-20231208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-041428
- JSON: https://secwatch.observer/filing/0001628280-23-041428.json
- Plain text: https://secwatch.observer/filing/0001628280-23-041428.txt

## Key facts
- Debt Financings
  Niagen Bioscience, Inc. amended revolving credit of up to $10.0 million with Western Alliance Bank at 8.25% per year maturing November 12, 2025.
  - Instrument: revolving credit
  - Principal: up to $10.0 million
  - Counterparty: Western Alliance Bank
  - Rate: 8.25% per year
  - Maturity: November 12, 2025
  - Event: amendment
  source text: the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”). The Credit Agreement provides for a revolving credit line of up to $10.0 million. The Amendment extended the maturity date of the revolving credit line under the Credit Agreement to November 12, 2025 and also increased the interest rate to be calculated at a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm
- Material Agreements
  Niagen Bioscience, Inc. amended Amendment to Business Financing Agreement with Western Alliance Bank valued at Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate (effective 2023-12-08).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Western Alliance Bank
  - Value: Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate
  - Effective: 2023-12-08
  source text: On December 8, 2023, ChromaDex Corporation (the “Company”), and the Company’s wholly owned subsidiaries, ChromaDex, Inc., a California corporation, and ChromaDex Analytics, Inc., a Nevada corporation (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the business financing agreement (as amended, the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023041428/0001628280-23-041428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.